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Magainins are a family of antimicroblal peptides present m the skm extracts of Xenopus laevis Both magainin-I and -2 do not have any significant 
effect on the activity of protein kinase C (PKC) Magamin- was found to be readily phosphorylated by PKC to 0.5 mo13ZP/mol of peptide. Neither 
magainin-1, which has a sequence of S8AGK and not S8AKK as in the case of magamin-2. nor the magamin- analogue with substitution of Ala 
for Sep was phosphorylated by the kinase, suggestmg that Se? is the phosphorylation site of magainin-2 One synthetic analogue of magamin, 
designated magaimn B, which has a greater tendency for a-helix formation m non-aqueous environment than the parent peptlde resulting from 
substitution of Se?, Gly’-‘. and Gly’* with Ala in magainin-2-amide, is a potent inhlbitor of PKC. This peptide inhibits all three PKC lsozymes 
with IC,, less than 20 PM. Magamin B also inhibits the bindmg of PH]phorbol 12.13-dibutyrate to the kmase. These results suggest that magainin-2 
may be modified by PKC through phosphorylation and that certain synthetic analogues of magaimns may be used as inhibitors of PKC. 
Protem kmase C; Inhlbltor: Magainm, Phosphorylation 
1. INTRODUCTION 
Two closely related magainin peptides with 23 amino 
acid residues, designated magainin-1 and -2, have been 
shown to display antimicrobial activity toward Gram- 
positive and Gram-negative bacteria, fungi, and pro- 
tozoa [1,2]. Recently, a series of magainin analogues 
having a greater growth inhibitory activity toward a 
variety of microbes by one to two orders of magnitude 
than the parent peptides have been synthesized [3]. 
Despite considerable effort focused on the therapeutic 
application of magainins in the treatment of infectious 
diseases, little is known about their mechanism of ac- 
tion. Because magainins have a sequence typical of an 
amphiphilic a-helical structure, it has been speculated 
that these peptides affect membrane function [1,3]. 
Protein kinase C (PKC) has been implicated in 
transmembrane signaling to regulate the functions of 
cell surface receptors, transporters, ion pumps, and ion 
channels 141. This enzyme preferentially 
phosphorylates erine and threonine residues located at 
the amino- and/or carboxyl-terminus of a cluster of 
basic amino acids [5]. Several cationic antimicrobial 
amphiphilic peptides having similar structures as 
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magainins are known inhibitors of PKC [6-81. To in- 
vestigate the biological action of magainins, we ex- 
amined the effect of two magainins and a synthetic 
analogue on PKC activity under in vitro assay condi- 
tions. We found that both magainin-1 and -2 had no 
significant effect on the PKC activity at concentrations 
up to lOOpM, whereas a synthetic analogue, named 
magainin B, was a potent inhibitor of all three PKC 
isozymes. Magainin-2, which has a substrate-like 
amino acid sequence motif, S’GKK, was readily 
phosphorylated by PKC. Although magainin B has the 
pseudosubstrate-like sequence 191, its inhibitory effect 
was not relieved by increasing the concentration of a 
protein substrate, but rather by the addition of 
phosphatidylserine (PS) and diacylglycerol. Magainin 
B also inhibited the binding of phorbol ester to the 
kinase. These results indicate the potential application 
of magainin B as a potent inhibitor of PKC. 
2. MATERIALS AND METHODS 
The following materials were obtained from the indicated sources: 
histone IIIS, protamine sulfate, and EGTA from Sigma; [Y-~‘P]ATP 
and [‘H]PDBu from DuPont New England Nuclear; PS and 
dioleoylglycerol (DOG) from Avanti Polar Lipids, Birmingham, AL; 
PDBu from LC Services Corp., Woburn, MA; magainin-1 
(GIGKFLHSAGKFGKAFVGEIMKS), and magainin-2 
GIGKFLHSAKKFGKAFVGEIMNS), from Peninsula Laboratories, 
Belmont, CA; and Nonidet P-40 (NP-40) from Pharmacia LKB 
Biotechnology; GF/C glass fiber filters and phosphocellulose P-81 
paper from Whatman. 
Magainin B (GIGKFLHAAKKFAKAFVAEIMNS-NHz) was syn- 
thesized and purified as previously described [3]. Homogeneous rat 
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bram PKC ~sozymea [lo] and the catalytic fragment of PKC (PKM) 
[1 1] were prepared as previously described. Phosphorylation of the 
substrates and measurement of [3H]PDBu binding were done with 
the mired mlceller asray [12]. The concentration5 of the synthetic 
peptides were calculated from ammo aud analyst,. Calculations of 
kmetic constant5 and ligand bmding parameters were sarrled out by 
a computer program designed for maklng statl,tlcal analyslc of a 
group of dose-rerponre curves [13]. 
3. RESULTS 
Initial experiments were carried out to determine if 
magainins and the synthetic analogues of magainins af- 
fect PKC activity. Neither magainin-1 nor magainin-2, 
at their effective antimicrobial concentrations 
(< 100 PM), have any inhibitory effect on the kinase ac- 
tivity, whereas magainin B is a potent inhibitor of the 
kinase. We noticed that magainin-2, but not 
magainin-1, was readily phosphorylated by PKC to ap- 
proximately 0.5 mol 32P/mol peptide (Fig. 1). The 
same extent of phosphorylation of the peptide was 
achieved by PKM. Phosphorylation of magainin-2 by 
PKC was stimulated by Ca’+, PS, and DOG, whereas 
the reaction catalyzed by PKM was not affected by 
these activators. Phosphorylation of magainin-2 by 
PKC displayed cooperativity with respect to the con- 
centration of the peptide (Fig. 2). At saturating concen- 
trations of PS (lOOpg/ml) and DOG (20pg/ml), the 
kinetic parameters were: Hill’s coefficient, 2.28 f 0.15; 
s1/2, 20.1 + 1.39 ,xM; and Max, 1325 ? 
27.7 nmol/min/mg. At a higher concentration of the 
peptide (greater than 50 PM), the rate of phosphoryla- 
tion was reduced slightly. Phosphorylation of 
magainin-2 by PKM in the absence of the activator ap- 
pears to follow a hyperbolic saturation kinetics. The 
kinetic parameters were: Hill’s coefficient, 1.23 k 0.05; 
Sl/Z, 23.4 rfr 1.15pM; and I’,,,, 2133 f 
53.1 nmol/min/mg. 
PKC and PKM could not phosphorylate magainin-I 
to any significant extent (data not shown). Magainin-1 
and -2 differ in their amino acid sequences at residues 
10 and 22. Lys” and AsnZ2 in magainin-2 are replaced 
by Gly” and LYS~~ in magainin-1. Replacement of 
Lys” in magainin-2 by Gly abolishes the Ly~‘~-Lysr’ se- 
quence, a motif recognized by PKC as a substrate. 
These results suggest that Se? is the phosphorylation 
site of magainin-2. 
Magainin B is an analogue of magainin-2-amide ob- 
tained by substitutions of Se?, Gly13, and Gly18 with 
Ala, which results in increased propensity to a-helix 
formation and antimicrobial activity [3]. This 
modification also abolishes the potential phosphoryla- 
tion site of PKC. Neither PKC nor PKM 
phosphorylates magainin B to any significant extent. 
Although magainin B is not a substrate of PKC, this 
peptide inhibited PKC isozymes with slightly different 
potency: the ICSO values were 15.3 ? 1.71, 9.9 -+ 0.95 
and 14.6 f 1.56kM for the type I, II, and III isozymes, 
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Fig. 1 Stolchlometry of phosphate mcorporatlon Into magainin-2 by 
PKC and PKM. hlagamin-2 (25 ph4) was Incubated uith 1.45 pg/ml 
of type II PKC isozyme (0) or PK;hl (A.) under the standard assaq 
condition containing 100 ,ug/ml of PS, 20 pg/ml of DOG (for PKC) 
or 1 mM EGTA (for PKM). AlIquor< were withdrawn at Indicated 
Intervals. and phosphate mcorporatlon into the pepude was 
measured as described m sectIon 2 
respectively (Fig. 3A). Despite the fact that magainin B 
has a similar structural motif as a PKC 
pseudosubstrate, in which the phosphorylatable Se? is 
replaced with Ala, inhibition of PKC was not alleviated 
by increasing concentration of histone 111s (data not 
shown). Moreover, PKM is less sensitive to inhibition 
by magainin B than PKC. At the highest concentration 
of magainin B (150 PM) tested, greater than 75% of the 
PKM activity remained. Phosphorylation of protamine 
sulfate, known as a Ca’+/phospholipid-independent 
substrate of PKC, was not significantly affected by 
magainin B at a concentration of 100 PM. Magainin B 
also inhibited the binding of [3H]PDBu to PKC II with 
an ICso value of 25.5 -t 4.73 PM (Fig. 3B). These data 
indicate that the inhibitory action of magainin B is 
mediated primarily through interaction with the 
regulatory rather than the catalytic domain of PKC. 
Peptlde Concentration ( ,,I1 1 
Fig. 2. Comparison of the rate of phosphorylation of magaimn-2 by 
PKC and PKM. IncorporatIon of “P mto the peptide was measured 
under standard assay conditions contaming lOOpg/ml of PS, 
20 pg/ml of DOG (for PKC, l ) or 1 .O mM of EGTA (for PKM, n ). 
The kmetlc parameters were obtamed by computer analysis. 
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Fig. 3. (A) Inhibition of the three PKC isozymes and PKM by 
magainin B. The kinase activities of type I (12). II (A) and III (0) 
PKC and PKM (0) were measured with histone 111s as substrate in 
the presence of 1.5 pg/ml of each kinase under the standard assay 
conditions containing 60~g/ml of PS and 20,~g/ml of DOG (for 
PKC) or 1 mM EGTA (for PKM). The kinase activity without 
magainin B was taken as 100%. (B) Inhibitton of [‘H]PDBu bmding 
by magainin B. The [3H]PDBu binding was measured with 1.7 pg/ml 
of type II PKC and the bindmg without magaimn B was taken to be 
100%. 
The effects of PS and DOG on the inhibition of PKC 
by magainin B were investigated. In the presence of 
20 PM of magainin B, the concentrations of PS re- 
quired for half-maximal kinase activity, Ai,2 , were 
67.0 f 4.74, 77.4 & 4.67, and 64.4 t 3.80hg/ml for 
PKC I, II, and III, respectively, and those values for 
PKC I, II, and III in the absence of the peptide were 
36.1 f 1.52, 38.9 & 0.76, and 24.3 t 1.87pg/ml, 
respectively (Fig. 4A). At PS concentrations less than 
40 pg/ml (6.5 mol%), 20 PM of magainin B was suffi- 
cient to inhibit all three PKCs for more than 90%. In- 
hibition of all three PKCs by magainin B was 
completely reversed by increasing PS concentration. In 
the presence of 40 PM of magainin B, the A 1,~ of DOG 
20 40 60 80 100 120 
~5 c0ncentratlon ( vg/ml 1 
0 IO 20 30 
CLOG c~ncentrat~an ( vg/ml 1 
Fig. 4. Effect of magainin B on type I, II, and III PKC activities in 
the presence of varied concentrations of PS and DOG. PKC I (o,‘.‘), 
II (A , A), and 111 (D, q ) were assayed in the presence (0, A , n ) or 
absence (111, A , 0) of magainin B ((A), 25 pM; and (B) 40 PM) as 
described in section 2 except for varymg concentrations of PS and 
ZO~g/ml of DOG (A) or for varying concentrattons of DOG and 
100 pg/ml of PS (B). The highest activity of each isozymes measured 
in the absence of the magamin B was taken to be 100%. 
for all three PKCs was increased by at least 3-fold 
(Fig. 4B). The Ai,2 of DOG in the presence of 40 PM 
of magaininB was 3.35 f 0.31, 7.63 -t 0.83, and 3.19 ? 
0.42 pg/ml for PKC I, II, and III, respectively. In com- 
parison, the At/z values for PKC I, II, and III in the 
absence of the peptide were 1.22 + 0.09, 2.14 f 0.23, 
and 1 .O -t 0.04 pg/ml, respectively. Thus, magainin B 
inhibits PKC by interfering with the interaction of the 
lipid cofactors with the regulatory domain. 
4. DISCUSSION 
The antimicrobial activities of magainins and their 
synthetic analogues appear to be related to their w 
helical contents in helicogenic environments, such as 
cell membranes [3]. Phosphorylation of these com- 
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pounds by protein kinase may reduce the hydrophobici- 
ty and renders them less effective. This presumptive 
detoxification mechanism apparently is not functioning 
in the microbes, in which the PKC-like activity has not 
been identified. Since the naturally occurring 
magainin-1 and -2 have no inhibitory effect on PKC at 
concentrations up to 100 PM, we suspect that the effect 
of magainins on the mammalian cells is not mediated 
by PKC. However, the PKC-mediated phosphorylation 
of magainin-2, but not magainin-1, could reduce its 
hydrophobicity and membrane-disrupting effect on the 
mammalian cells. Thus, magainin-2 may be a more 
desirable therapeutic agent than magainin-1. 
Magainin-2 is phosphorylated by PKC up to 
0.5 mol/mol of the peptide. Since there is only one 
potential phosphorylation site of PKC, these results in- 
dicate that only 50% of the molecule is 
phosphorylated. This may be due to the existence of 
multiple conformers of this short chain peptide in the 
aqueous environment and only some of them are PKC 
substrates. Another explanation could be that the pep- 
tide is present as polymer, similar to melittin [14], 
resulting in steric hindrance at some of the 
phosphorylatable serine residue. In vivo, certain ac- 
tions of PKC seem to result from the phosphorylation 
of ion pumps and ion channels [ 151. It is of interest to 
determine the effect of phosphorylation of magainin-2 
on the conductivity of lipid membrane. Introduction of 
a negatively charged phosphate group could elec- 
trostatically interfere with anion transport. 
PKC I and III with ICso near 20 PM as well as myosin 
light chain kinase with I&, of greater than 60 PM. In- 
hibition of PKC by magainin B apparently results from 
interference with the binding of phospholipid and 
diacylglycerol (or phorbol ester) to the regulatory do- 
mains of the kinase. This interference could result from 
the interaction of magainin B with the lipid vesicles or 
alternatively a direct interaction of the peptide with the 
kinase. We noticed that incubation of magainin B with 
PKC in the absence of lipid caused an inactivation of 
the kinase as was observed for the acidic phospholipid- 
induced inactivation [ 171. This finding supports the 
contention that magainin B also interacts directly with 
PKC and, thus, conferring the unique specificity of in- 
hibition. 
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